1-4 of 4
Olaf Walter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

C1-INH and atiii inhibit vaso-occlusion and vascular inflammation in sickle cell disease mice

Free
John Belcher, Julia Nguyen, Fuad Abdulla, Chunsheng Chen, Conglin Ruan, Larisa Belyanskaya, Sigurd Knaub, Olaf Walter, Gregory Vercellotti
Journal: Blood
Blood (2025) 146 (Supplement 1): 835.
https://doi.org/10.1182/blood-2025-835
Published: 2025
Journal Articles

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Free
Robert Klamroth, Toshko Lissitchkov, MD, Luminita Rusen, Olaf Walter, MD MBA, Johann Bichler, PhD, K John Pasi, Andreas Tiede, MD PhD, Sigurd Knaub, PhD
Journal: Blood
Blood (2015) 126 (23): 547.
https://doi.org/10.1182/blood.V126.23.547.547
Published: 2015
Journal Articles

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Free
Craig M. Kessler, MD, Bruce A. Schwartz, PhD, Oliver Hegener, Olaf Walter, MD, Sigurd Knaub, PhD
Journal: Blood
Blood (2010) 116 (21): 1424.
https://doi.org/10.1182/blood.V116.21.1424.1424
Published: 2010
Journal Articles

Clinical Efficacy and Safety of Wilate ® , A New Generation, High-Purity VWF/FVIII-Concentrate with Optimized Pharmacokinetic Properties in the Treatment of Von Willebrand Disease.

Free
Jerzy Windyga, MD, Antoaneta Zarkova, MD, Olaf Walter, MD, Guenter Auerswald, MD
Journal: Blood
Blood (2005) 106 (11): 1795.
https://doi.org/10.1182/blood.V106.11.1795.1795
Published: 2005